Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BAVARIAN NORDIC A S. We currently have 4 research reports from 1 professional analysts.
|15Mar17 07:00||GNW||Bavarian Nordic Awards Restricted Stock Units to Corporate Management|
|15Mar17 06:48||GNW||Bavarian Nordic Announces Annual Report 2016|
|10Mar17 08:54||GNW||Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer|
|09Mar17 16:30||GNW||Bavarian Nordic to Host Full Year 2016 Results Conference Call|
|23Feb17 15:21||GNW||Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV|
|17Jan17 07:00||GNW||Henrik Birk Appointed Chief Operating Officer of Bavarian Nordic|
|04Jan17 13:26||GNW||Bavarian Nordic Provides Update on Anticipated Timing of PROSPECT Study|
Frequency of research reports
Research reports on
BAVARIAN NORDIC A S
BAVARIAN NORDIC A S
Progressing at cruising speed
02 Jun 16
Following a $100m private placement, Bavarian Nordic is ready to push its pipeline forward and create long-term value. Smallpox vaccine Imvamune is being stockpiled by the US and Canadian governments and Prostvac is advancing towards top-line Phase III data in 2017. The MVA-BN RSV vaccine is progressing towards mid-stage studies, while Phase II trials of CV-301 and Prostvac in combination with checkpoint inhibitors will start by mid-year. Our updated valuation of DKK13.4bn includes RSV and the latest bulk Imvamune order.
Private placement trumps IPO
26 Apr 16
The current weak US IPO conditions have resulted in a slight change of plan for Bavarian Nordic. It recently shelved its US listing plans and instead completed a private share placement, which raised c $100m vs. the expected $86m in the F-1 filing. New funds will be used for the same purposes as the IPO, namely advancing the development of CV-301, MVABN RSV and for capex. Prostvac has passed its first interim analysis and the Phase III trial will continue without modification.
Seeking a cash injection from the US
17 Feb 16
Bavarian Nordic’s intention to list on NASDAQ is a strategic move to broaden its appeal to US investors and raise additional funds to accelerate clinical development of multi-tumor cancer immunotherapy CV-301 and respiratory syncytial virus vaccine MVA-BN RSV and to expand its manufacturing capacity. As a well-funded revenue generating company, it should still appeal to investors despite market headwinds. While pricing is to be determined, the likely timing of the proposed IPO represents an attractive entry point for US investors ahead of a newsflow-rich 2016.
Advancing the pipeline with start of RSV trial
21 Aug 15
Bavarian Nordic has now commenced the planned Phase I study of MVABN RSV. Advancing the earlier-stage pipeline is one of Bavarian Nordic’s key priorities, hence this represents an important step. RSV could be a significant opportunity, particularly in adults, and we expect Bavarian to consider partnering, albeit not until at least Phase II. Our valuation, which does not yet include RSV owing to its early stage of development, is largely unchanged at DKK12.6bn.
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.